Precigen appoints phil tennant as chief commercial officer to spearhead first potential gene therapy launch

–  company strengthens focus on building and optimizing commercial readiness and pre-launch activities for prgn-2012 in recurrent respiratory papillomatosis  – germantown, md. , july 23, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of phil tennant as the company's chief commercial officer.
PGEN Ratings Summary
PGEN Quant Ranking